Agenus (Formerly known as Antigenics Inc. - Lexington, MA)’ HerpV Phase 2 Study to Treat Genital Herpes Completes Enrollment

LEXINGTON, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced it has completed patient screening in its Phase 2 randomized, double-blind, multicenter study for HerpV, a recombinant “off-the-shelf” therapeutic vaccine candidate for the treatment of genital herpes in herpes simplex virus-2 (HSV-2) positive patients. HerpV contains Agenus’ QS-21 Stimulon® adjuvant (QS-21 Stimulon).